S-AVANT observational study follow up
Research type
Research Study
Full title
S-AVANT. Follow-up to the AVANT study up to 8 and 10 years (median follow-up) in patients with colon carcinoma.
IRAS ID
210852
Contact name
Nelly Roldan
Contact email
Sponsor organisation
GERCOR
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
NCT02228668, www.clinicaltrials.gov
Duration of Study in the UK
0 years, 3 months, 21 days
Research summary
This is a follow-up study of participants previously randomised in the AVANT study at 8 and 10 years median follow-up. No visits to the study site, and no assessments or clinical examinations are required as data will be obtained from the medical notes of those participants who were randomised into the previous AVANT study. Data will be collected for: Date of last contact/follow-up; date and type of first relapse, first treatment of metastatic disease (chemotherapy and local treatment), date and type of other cancer, biomarkers and adverse events occurred after AVANT database lock (31 Aug 2012) and related to bevacuzimab or capecitabine administered in the AVANT study; survival status (alive or deceased).
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
17/WM/0290
Date of REC Opinion
20 Sep 2017
REC opinion
Further Information Favourable Opinion